Biotech | January 03, 2022
Ascletis expands ritonavir oral tablet production
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The medicine is now approved for eight indications across five different types of cancer in China.
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Subscribe To Our Newsletter & Stay Updated
